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the warfarin and $10,195 (12,780) in the warfarin and NSAID groups (p < 0.01). 
CONCLUSIONS: This analysis did not identify a difference in the odds of having a 
GI bleed when on warfarin or warfarin plus NSAIDS. Unexpectedly, there were sig-
niﬁcantly lower costs for the warfarin plus NSAIDs group. These results should be 
interpreted with caution due to the small sample size and limitations of retrospective 
analysis.
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REPORTING SYSTEM
Seddoh SA1, Guo JJ2, Ajayi FO3, Wigle P1
1University of Cincinnati, Cincinnati, OH, USA, 2University of Cincinnati Medical Center, 
Cincinnati, OH, USA, 3Procter & Gamble Company, Mason, OH, USA
OBJECTIVES: Pregnant women may use promethazine or ondansetron for nausea 
and vomiting during pregnancy (NVP). The long-term safety and its potential risks 
on the fetus and newborns are widely unknown. Promethazine has a black boxing 
warning for contraindicating its use in infants and young children. The purpose of 
this study was to quantify and describe adverse events (AEs) related to these two 
medications in child-bearing age women and young children. METHODS: The data 
source was the FDA’s Adverse Events Reporting System database from 1997 to 2006. 
Using a retrospective data analysis, AEs for all patients with study drugs were com-
pared to that for children ages 0–6 years old and women of child-bearing age (CBA) 
15- 50 years old. The annual frequencies of AEs for both study drugs were analyzed 
and stratiﬁed by age group and gender. The related AEs were categorized by clinical 
outcomes, pregnancy outcomes, route of administration, and duration of therapy. 
RESULTS: A total of 392,229 AEs for promethazine and 282,056 AEs for ondanset-
ron were reported. Of those, 13.7% of ondansetron and 22% promethazine AEs were 
for CBA women with the peak for age 35–50; while 13.1% ondansetron and 13.8% 
promethazine AEs were for children age 0–6 with the peak for age 0–2. There were 
23.68% and 13.54% AEs related to promethazine and ondansetron long-term use 
(greater than 90 days) among CBA women, respectively. The most common routes of 
administration were oral and intravenous. For CBA women, the frequent AE preg-
nancy outcomes were maternal complications (26%), premature labor (9%), maternal 
drugs affecting fetus (8%) and spontaneous abortion (4%); while the most frequent 
AEs for children were neonatal respiratory arrest (0.25%) and neonatal apneic attack 
(0.17%). CONCLUSIONS: AEs of promethazine and ondansetron among children 
and CBA women are common. The risk of their off-label use for the long-term treat-
ment of NVP should be recommended with cautions.
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OBJECTIVES: The etiology of functional dyspepsia (FD) is debated. However, no 
published data exist on the associated co-morbid conditions with FD. This study aimed 
to assess the prevalence, services, and costs related to co-morbid conditions associated 
with FD. METHODS: Retrospective database analysis on a 4-year study period, from 
January 1, 2001, through December 31, 2004 using payroll data and adjudicated 
health insurance medical and prescription claims on more than 300,000 employees. 
Study comparisons were performed among employees with FD and propensity-score-
matched employees without FD (controls). Outcome measures included the preva-
lence, costs and utilization of health services for various comorbid conditions as 
deﬁned by the Agency for Healthcare Research and Quality (AHRQ). RESULTS: 
Employees in cohort FD (N = 1669) and a 50:1 matched control-cohort (N = 83,450) 
were compared. Employee with FD were more likely to have all major diagnostic 
categories (MDC) including digestive system, blood and blood forming organs, mental 
disorders, infections and parasitic disease, etc. except pregnancy and prenatal related 
disease, compared to matched controls. The top MDC prevalence ratios between the 
two groups were for digestive systems (6.3:1), blood and blood form organs (2.6:1), 
mental disorders (2.1:1), and infectious & parasitic disease (2.0:1). More interestingly, 
18 of the top 30 most prevalent AHRQ “speciﬁc” categories were non-speciﬁc with 
the terms like “other” or “undeﬁned” in the title. Moreover, annual medical costs for 
the FD cohort were greater than for controls in 155 (59%) of the 261 AHRQ’s Speciﬁc 
Categories and signiﬁcantly greater (P ≤ 0.05) in 76 categories (29%). Similarly, the 
services were greater for 179 (69%) of the 261 Speciﬁc Categories and signiﬁcantly 
greater (P ≤ 0.05) in 110 categories (42%). CONCLUSIONS: Thisstudy showed excess 
comorbidity in employees with FD compared to employees without FD, might be a 
major determinant factors for excess health-care services and health-care costs of 
functional dyspepsia.
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OBJECTIVES: Hepatitis C affects approximately 180 million people worldwide. It is 
one of the main causes of liver disease and is the predominant etiology for liver 
transplantation. This study performs a systematic review and meta-analysis of pub-
lished randomized controlled trials comparing efﬁcacy of peginterferon-alpha-2a 
versus peginterferon-alpha-2b both in association with ribavirin in order to assess 
which is more effective in the treatment of HCV infection. METHODS: A thorough 
search in MEDLINE, Lilacs, Cochrane library and Embase databases was conducted 
in the last quarter of 2009. Manual searches in specialized websites were also carried 
out. Included studies were those which evaluate treatment efﬁcacy of peginterferon 
alpha-2a versus peginterferon alpha-2b both plus ribavirin for hepatitis C treatment 
in naïve patients or nonresponders to other therapies not co-infected with HIV. 
According to heterogeneity test, a ﬁxed or a random-effect models was adopted for 
meta-analysis. RESULTS: A total of 570 citations (databases citation without dupli-
cates plus manual searches) were found but only seven met the inclusion criteria: 1) 
Ascione, 2009; 2) Rumi, 2009; 3) McHutchison, 2009; 4) Yenice, 2006; 5) Scotto, 
2008; 6) Kolakowska, 2008; 7) Berak, 2007. All studies are randomized controlled 
trials. Overall, peginterferon-alpha-2a has shown higher sustained virological response 
(SVR) as compared to peginterferon-alpha-2b: 51.7% versus 42.4% (RR = 1.23, IC 
95% 1.10 – 1.38, assuming a ﬁxed-effect model). For genotypes 1/4: 42.1% versus 
33.3% (RR = 1.11, IC 95% 1.02 – 1.20, assuming a ﬁxed-effect model) and for geno-
types 2/3: 79.2% versus 73.8% (RR = 1.11, IC 95% 1.01 – 1.22, assuming a ﬁxed-
effect model). CONCLUSIONS: These ﬁndings suggest that peginterferon-alpha-2a is 
associated with a higher clinical response than peginterferon-alpha-2b indicating that 
it should be used as the standard-of-care therapy. Our results are in line with another 
recent published systematic review (Awad, 2009) which concluded that peginterferon-
alpha-2a has a higher SVR as compared to peginterferon-alpha-2b, with similar safety 
proﬁle.
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OBJECTIVES: To investigate whether the 5-HT3 receptor antagonists—ondansetron, 
granisetron, tropisetron, and dolasetron—used for the prevention of post-operative 
nausea and vomiting (PONV) differ in efﬁcacy. METHODS: A meta-analysis was 
conducted using published studies. A systematic literature search within Pubmed and 
the Cochrane Library for randomized, controlled, double-blinded studies measuring 
efﬁcacy in terms of PONV prophylaxis was conducted. The odds of patients exempted 
from PONV and post-operative vomiting (POV) within each study arm 24 hours after 
surgery were the primary indices of drug efﬁcacy. Indirect comparisons using random 
effect models were conducted. Subgroup analyses excluding controversial studies and 
controlling amount of dose and administration route were also conducted. RESULTS: 
A total of 82 studies were identiﬁed, representing 15,709 patients. In terms of prevent-
ing PONV, the analysis indicated that granisetron was statistically signiﬁcantly better 
than ondansetron (odds ratio(OR) = 1.46, 95% conﬁdence interval(CI):1.08–2.00) 
and dolasetron(OR = 1.56, 95%CI: 1.03–2.34); no other statistically signiﬁcant rela-
tionships comparing either two of the four drugs were found. In terms of preventing 
POV, the four antiemetic drugs had comparable efﬁcacy: granisetron showed similar 
efﬁcacy as compared to ondansetron(OR = 1.61, 95%CI: 0.99–2.63), tropisetron(OR 
= 1.70, 95%CI: 0.95–3.05) and dolasetron(OR = 1.35, 95%CI: 0.78–2.27); ondanset-
ron exhibited comparable efﬁcacy as compared to tropisetron(OR = 1.06, 95%CI: 
0.63–1.79) and dolasetron(OR = 0.84, 95%CI = 0.52–1.31); tropisetron and dolas-
etron were also similar in efﬁcacy(OR = 0.80, 95%CI = 0.44–1.37). Subgroup analyses 
also found that the four drugs did not differ in efﬁcacy. All 5-HT3 receptor antagonists 
were statistically signiﬁcantly better than placebo. CONCLUSIONS: With respect to 
PONV prophylaxis, granisetron was statistically signiﬁcantly better than ondansetron 
and dolasetron; ondansetron, tropisetron, and dolasetron exhibit similar efﬁcacy. With 
respect to POV prophylaxis, ondansetron, granisetron, tropisetron, and dolasetron 
appeared to have comparable efﬁcacy.
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OBJECTIVES: Research has suggested that admissions for diverticular disease (DD) 
are on the rise in Western countries, particularly among a younger patient population. 
However, relatively little is known about how this increase has impacted the use of 
surgical procedures for the management of DD. The goals of this study were a) to 
determine temporal trends in the use of surgical procedures (laparoscopic colectomy 
[LC] and open colectomy [OC]) for DD, and b) to investigate temporal changes in 
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surgical procedures among younger patients for the management of DD. METHODS: 
Using a nationwide commercial claims database, a retrospective cohort was identiﬁed 
who had undergone LC (n = 2095) or OC (n = 5971) between 4th quarter, 2005 
through 1st quarter, 2009. 2000 U.S. Census data was used to calculate age-adjusted 
temporal trends in the overall surgical procedure and logistic regression was used to 
determine the time trends in each surgical procedure, adjusting for age, gender, and 
the type of beneﬁt plan. RESULTS: A total of 8,066 surgical procedures were per-
formed during the study period (mean age = 53 ± 11, 55.7% Male). Quarterly mean 
number of surgical procedures(LC+OC) performed was 576 (SD = 39) and the annual 
mean number of LC+OC from 2006 to 2008 was 2297 (SD = 107). Quarterly age-
standardized surgical procedures(LC+OC) for DD declined by 9.26% for patients 
younger than 45, whereas overall surgical rate increased by 3.2% for older patients. 
The odds of having a LC over OC declined by 8% each consecutive quarter (95% CI 
0.91, 0.93) while controlling for other covariates. CONCLUSIONS: Data suggest that 
there was a slight decline over time in surgical procedures for younger patients. The 
reasons for the decline in surgical procedures for younger patients may be due to recent 
studies suggesting that DD is not more aggressive in younger patients as initially 
reported, and that the conservative medical treatment may be more appropriate with 
this population.
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OBJECTIVES: The National Health and Nutrition Examination Survey (NHANES) 
estimates chronic HCV infection prevalence at 1.3% of the US population or ∼3 
million individuals, with a peak HCV antibody prevalence of 4.3% for those born in 
the 1950s. From NHANES we can assume that 79.7% of HCV antibody positive 
patients will not clear the virus; therefore we expect to observe 3% chronic HCV 
infection in this peak population. METHODS: Patients diagnosed with HCV (ICD-9 
codes 070.41, 070.44, 070.51, 070.54, 070.70, 070.71, V02.61) between 2002 and 
2006 were identiﬁed in MedStat commercial health insurance claims. We calculated 
age-sex prevalence of diagnosis by birth year. A log-regression model was constructed 
to examine the relationship between prevalence of HCV diagnosis and number of 
observation years. RESULTS: The prevalence of patients with a HCV diagnosis in 
2006 was 0.12%. The prevalence of patients with HCV diagnosis was consistent in 
each year’s claims, peaking in those born between 1950–1955. Longitudinal data 
across ﬁve years demonstrated increasing diagnosis rates with additional years of 
observation, according to a log function. Modeled for 10 years of observation, total 
diagnosed prevalence was estimated at 0.29% (R2 = 0.99); peak prevalence was 
1.35% for males and 0.64% for females for those born in the early 1950s. CONCLU-
SIONS: In each year examined, the claims-based prevalence of an HCV diagnosis was 
about 10% of the NHANES estimated prevalence (0.12% vs. 1.3%). Although diag-
nosed HCV prevalence increased with years of observation, the 10-year modeled 
diagnosis prevalence was only 22% of NHANES estimated prevalence. Like in 
NHANES, peak prevalence of HCV in claims was observed in patients born in the 
1950s. This suggests that many patients have long-standing HCV infection and are at 
possible risk of decompensation. Further research is warranted to examine whether 
HCV-related advanced liver disease is more commonly coded in claims data.
GASTROINTESTINAL DISORDERS – Cost Studies
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OBJECTIVES: Low persistency for oral 5-ASA drugs is associated with increased risk 
of relapse of ulcerative colitis(UC) and subsequent costs. We constructed a one-year 
budget impact model to compare annual all-cause direct incremental costs(IC) of 
treatment for the health plan(HP) per mild-to-moderate UC patient using oral 5-ASA 
drugs and associated persistency rates(PRs). METHODS: Assuming a budget holder’s 
perspective for a one-year horizon, the model analyzed the impact of PR on total UC 
related all-cause direct IC. PRs for 5-ASA drugs(mesalamine CR[CRM] 250mg 7% 
& 500mg 10%, balsalazide disodium[BD] 10%, olsalazine[OLS] 10%, mesalamine 
DR[DRM] 9%, multi matrix system mesalamine[MMX] 20%) were derived from 
published literature. UC patients within the HP were distributed to drugs based on 
September 2009 market share data and classiﬁed as persistent if they reﬁlled within a 
timeframe of up to twice the duration of their prescription. Annual UC-related phar-
macy costs were calculated using net wholesale acquisition cost, and additional all-
cause direct ICs for patients with/without relapse were cited from published literature. 
Sensitivity analyses varying net drug costs and PRs were performed to determine 
impact on health care costs. RESULTS: Average annual all-cause UC costs per patient 
were: $13,135 CRM-250; $13,065 CRM-500; $12,914 BD; $12,804 OLS, $12,688 
DRM; $12,255 MMX. Inpatient costs were lower for MMX($5,667) as compared to 
market leader(DRM;$6,216) and lowest priced drug alternative(OLS;$6,343). Sensi-
tivity analyses indicated higher savings/patient for MMX than DRM($462 vs. $30, 
respectively). The primary driver for inpatient cost differences was the frequency of 
relapse reduced by persistency. A health plan with 1 million covered lives(2,300 UC 
patients) can save $401,000($0.03 per member/month) by switching 50% of UC 
patients to MMX. CONCLUSIONS: This analysis illustrates the impact of medication 
persistence on reduction of UC relapse and associated health care costs. Health plans 
may achieve savings by including drugs with high PRs in their formulary.
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OBJECTIVES: Colectomy is a standard procedure in complicated colonic diverticular 
disease (DD) including diverticulosis and diverticulitis. Although laparoscopic colec-
tomy (LC) has demonstrated some clinical advantages over open colectomy (OC), the 
true ﬁnancial burden, cost and reimbursement structures between the two surgical 
procedures remain unclear. The purpose of this study was to compare patient ﬁnancial 
burden, direct surgical costs and reimbursements for OC and LC procedures in DD. 
METHODS: Nationwide commercial claims database from 2003 through 2007 was 
used to identify 1,614 patients who had undergone OC (n = 1327) or LC (n = 287) 
for DD. Patient ﬁnancial burden (deﬁned by out-of-pocket [OOP] costs including 
co-pay, deductible and coinsurance), direct surgical costs, reimbursements and cost-
to-charge ratios for OC and LC were compared using the Student’s t-test and chi-
square test where appropriate. RESULTS: OC and LC groups differed with respect 
to mean age (60 and 64 years, respectively; p < 0.001) but did not differ in male/
female ratio. OOP costs were signiﬁcantly greater for OC ($410 vs. $350 for LC; p 
< 0.001). Both surgical costs and the reimbursements per case were signiﬁcantly less 
for OC ($4231 ± 98 and $1412 ± 35, respectively) than LC ($5246 ± 231 and $1809 
± 80 respectively; both p < 0.001). Cost-to-charge ratios were the same for both surgi-
cal procedures (0.38). CONCLUSIONS: This analysis demonstrated that patient 
ﬁnancial burden, as assessed by OOP costs, was moderately greater for open colec-
tomy, but the direct costs and reimbursements of OC were signiﬁcantly lower than 
LC. However, low surgical costs may be offset by potential increases in length of 
hospital stay due to longer recovery time for OC. Understanding differences in cost 
structures may be helpful in further investigations of the cost-effectiveness of these 
two surgical procedures in diverticular disease.
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OBJECTIVES: Crohn’s Disease (CD) and Ulcerative Colitis (UC), collectively termed 
Inﬂammatory Bowel Disease (IBD), are associated with hospitalizations, surgical pro-
cedures, and long-term medical follow up. The objectives of the current study were 
to quantify the national pediatric IBD burden in 2006 and stratify by demographics 
by determining the (1) number of hospitalizations; (2) number of days spent in the 
hospital; and (3) hospitalization costs. METHODS: The 2006 Kids’ Inpatient Data-
base was used to examine IBD in hospitalized children and adolescents 20 years and 
younger with a primary diagnosis of either CD or UC. Frequency of discharges, the 
total and mean length of stay (LOS) and costs were calculated, and stratiﬁed by various 
patient and hospital characteristics such as age, gender, expected primary payer, 
patient income, surgery status, teaching status, hospital size, location and region. 
RESULTS: In 2006, there were 10,777 IBD-related pediatric visits, of which 6,599 
were due to CD and 4,178 were due to UC. For CD and UC, respectively, there were 
37,175 and 27,810 days spent in the hospital; mean LOS was 5.63 and 6.66 days. 
The total and mean costs for CD were $66.3 million and $10,176, respectively. The 
total and mean costs for UC were $48.6 million and $11,836, respectively. For CD, 
0–5 year old patients had the highest mean LOS (8.10 days) and mean cost ($13,894), 
while, for UC, 11–15-year old patients had the highest mean LOS (7.49 days) and 
mean cost ($13,407). Patients with Medicaid had a higher mean LOS and cost than 
those with private insurance. Surgery increased mean LOS over 3 days and almost 
doubled the cost for IBD hospitalizations. CONCLUSIONS: IBD is a burdensome 
illness. Future research will determine if newer treatment options can reduce 
hospitalizations.
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OBJECTIVES: Functional dyspepsia is a common, morbid condition but data are 
limited on the indirect and direct costs for employees with functional dyspepsia or on 
its impact on productivity. Few data on absenteeism no objective information are 
available. This study aimed to assess functional dyspepsia’s incremental health beneﬁt 
costs and effects on absenteeism and work output (productivity). METHODS: We 
performed a retrospective analysis of payroll data and adjudicated health insurance 
